Research analysts covering ProQR Therapeutics.
Recent press releases and 8-K filings for PRQR.
ProQR Therapeutics N.V. Announces Encouraging AX-0810 Phase 1 Data, Development Candidate Selections, and 2026 Outlook
PRQR
New Projects/Investments
Guidance Update
- ProQR announced encouraging initial AX-0810 Phase 1 data, showing no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data, with target engagement data expected in H1 2026.
- The company selected Development Candidates for AX-2402 for Rett syndrome and AX-2911 for MASH, aiming to initiate a first-in-human clinical trial for AX-2402 in H1 2027.
- ProQR's strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to a strong financial position with runway into mid-2027.
Jan 8, 2026, 1:08 PM
ProQR Therapeutics N.V. Reports Q3 2025 Financial Position
PRQR
Earnings
Guidance Update
- ProQR Therapeutics N.V.'s cash and cash equivalents were €106,883 thousand as of September 30, 2025, a decrease from €149,408 thousand at December 31, 2024.
- The company's total assets decreased to €124,349 thousand by September 30, 2025, from €167,958 thousand at December 31, 2024.
- Total equity for ProQR Therapeutics N.V. stood at €57,071 thousand at September 30, 2025, down from €88,560 thousand at December 31, 2024.
- The €106.9 million in cash and cash equivalents as of Q3 2025 is expected to provide a financial runway into mid-2027.
Nov 6, 2025, 12:00 PM
ProQR Therapeutics Announces Q3 2025 Operating and Financial Results
PRQR
Earnings
New Projects/Investments
Guidance Update
- ProQR Therapeutics reported €106.9 million in cash and cash equivalents as of September 30, 2025, providing a cash runway into mid-2027.
- The company received CTA authorization for its lead program AX-0810, targeting NTCP for cholestatic diseases, and initiated a Phase 1 study in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end 2025.
- For the nine-month period ended September 30, 2025, ProQR reported a net loss of €33.3 million and research and development costs of €34.8 million.
Nov 6, 2025, 12:00 PM
ProQR Therapeutics N.V. discusses AX-0810 pipeline program and clinical trial initiation
PRQR
New Projects/Investments
Guidance Update
- ProQR Therapeutics N.V. hosted an analyst and investor event on November 3, 2025, to discuss its AX-0810 lead pipeline program, an RNA editing therapy targeting NTCP for cholestatic diseases.
- The Clinical Trial Application (CTA) for AX-0810 has been approved in Europe, initiating a first-in-human (FIH) trial to assess safety, tolerability, and pharmacokinetics (PK) in healthy volunteers.
- Initial safety, tolerability, and PK data for Cohort 1 of the AX-0810 trial are expected towards the end of 2025, with target engagement data for all cohorts anticipated in H1 2026.
- The company reported €119.8 million in cash and cash equivalents as of the end of Q2 2025, providing a financial runway into mid-2027.
Nov 3, 2025, 9:01 PM
ProQR Therapeutics Receives CTA Authorization for AX-0810 Phase 1 Study
PRQR
New Projects/Investments
Guidance Update
- ProQR Therapeutics N.V. has received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 study of AX-0810 in healthy volunteers.
- This authorization allows ProQR to begin dosing in the Phase 1 study, which will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics via biomarkers to establish proof of target engagement.
- AX-0810 is ProQR's lead investigational RNA editing oligonucleotide (EON) targeting NTCP, developed for the treatment of cholestatic diseases like primary sclerosing cholangitis and biliary atresia.
- ProQR will host a virtual Investor and Analyst Event on November 3, 2025, at 10 am ET, to discuss entering the clinic with AX-0810.
- The company anticipates the timing of initial Phase 1 clinical data for AX-0810 in Q4 2025.
Oct 20, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more